What to Know About the Alzheimer Drug Aducanumab (Aduhelm)

JAMA Intern Med. 2022 Aug 1;182(8):892. doi: 10.1001/jamainternmed.2022.1039.

Authors

Steven Woloshin^{1

2}, Aaron S Kesselheim³

Affiliations

¹ Dartmouth Institute, Lebanon, New Hampshire.
² The Lisa Schwartz Foundation for Truth in Medicine, Norwich, Vermont.
³ Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 35666531
DOI: 10.1001/jamainternmed.2022.1039

No abstract available

MeSH terms

Alzheimer Disease* / drug therapy
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized / therapeutic use
Drug Approval
Humans
United States
United States Food and Drug Administration

Substances

Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
aducanumab